Amgen Reclaims Rights From GSK To Grow In Ex-US Markets
This article was originally published in Scrip
Executive Summary
Amgen Inc. will reacquire ex-US rights to its cancer drug Vectibix (panitumumab) and bone drugs Prolia (denosumab) and Xgeva (denosumab) in 48 countries from GlaxoSmithKline PLC, which generated $111m in combined revenue from the products in 2014.
You may also be interested in...
Amgen-Dr Reddy's Build On India Alliance
Amgen is building on its alliance with Dr. Reddy’s Laboratories in India, shifting out certain products previously sold by GlaxoSmithKline in the country to the Hyderabad-based firm.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.
Venture Capital Fundraising Rebounds In Q1 As Mega-Rounds Dominate
Biopharma firms raised $6bn in the first quarter of 2024, the most of any quarter since Q2 2022. But without an increase in the number of companies raising funds, the rebound remains uneven.